Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
07 10월 2024 - 9:00PM
Business Wire
Combination of IL-15 and IL-21 robustly
augments NK and CD8 T cell activity
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company leveraging a deep understanding of immunobiology to develop
novel therapeutics to treat severe autoimmune and inflammatory
disorders, today announced that an abstract was accepted for poster
presentation at the 39th Annual Meeting of the Society for
Immunotherapy of Cancer. The conference will take place at the
George R. Brown Convention Center in Houston, Texas from November 6
to 10, 2024.
Title: Interleukin (IL)-15 and IL-21 synergistically enhance NK
and CD8+ T cell responses Presenting Author: Phoi Tiet, Senior
Research Associate, Equillium, Inc. Abstract Number: 908
Location: Exhibit Halls A & B Date: Saturday,
November 9, 2024
The abstract highlights that cytokines are a focus of
anti-cancer therapeutic development due to their central role in
regulating anti-tumoral immune responses, and that data
demonstrates that IL-15 and IL-21 synergistically augment NK and
CD8 T cells activities, which further enhanced their proliferation
and cytolytic function. With the ability to rescue T cell
dysfunction, this cytokine combination could be a promising
treatment approach to stimulating anti-tumor immune responses.
About Multi-Cytokine Platform and Multi-Cytokine Inhibitors
EQ101 & EQ302
Our proprietary multi-cytokine platform generates rationally
designed composite peptides that selectively block key cytokines at
the shared receptor level targeting pathogenic cytokine
redundancies and synergies while preserving non-pathogenic
signaling. This approach is expected to avoid the broad
immuno-suppression and off-target safety liabilities that may be
associated with other therapeutic classes, such as Janus kinase
inhibitors. Many immune-mediated diseases are driven by the same
combination of dysregulated cytokines, and we believe identifying
the key cytokines for these diseases will allow us to target and
develop customized treatment strategies for multiple autoimmune and
inflammatory diseases.
Current platform assets include EQ101, a clinical stage,
first-in-class, selective, tri-specific inhibitor of IL-2, IL-9,
and IL-15 for intravenous and subcutaneous delivery and EQ302, a
preclinical stage, first-in-class, selective, bi-specific inhibitor
of IL-15 and IL-21 for oral delivery.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel first-in-class immunomodulatory assets and product
platform targeting immuno-inflammatory pathways. EQ101: a selective
tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15;
recently announced positive results from a Phase 2 proof-of-concept
clinical study of patients with alopecia areata. EQ302: an orally
delivered, selective bi-specific cytokine inhibitor targeting IL-15
and IL-21; currently in pre-clinical development. The
multi-cytokine platform: generates rationally designed composite
peptides that selectively block key cytokines at the shared
receptor level targeting pathogenic cytokine redundancies and
synergies while preserving non-pathogenic signaling. Itolizumab: a
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells;
currently under evaluation in a Phase 3 clinical study of patients
with acute graft-versus-host disease (aGVHD) and exhibited positive
results in a completed Phase 1b clinical study of patients with
lupus/lupus nephritis in April 2024. Equillium acquired rights to
itolizumab through an exclusive partnership with Biocon Limited and
has entered a strategic partnership with Ono Pharmaceutical Co.,
Ltd., for the development and commercialization of itolizumab under
an option and asset purchase agreement.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of Equillium’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks that contribute
to the uncertain nature of the forward-looking statements include:
Equillium’s ability to execute its plans and strategies; risks
related to performing clinical studies; whether the results from
clinical studies will validate and support the safety and efficacy
of Equillium’s product candidates. These and other risks and
uncertainties are described more fully under the caption "Risk
Factors" and elsewhere in Equillium's filings and reports, which
may be accessed for free by visiting the Securities and Exchange
Commission’s website at www.sec.gov and on Equillium’s website
under the heading “Investors.” Investors should take such risks
into account and should not rely on forward-looking statements when
making investment decisions. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Equillium undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241007960831/en/
Investor Contact Michael Moore Vice President, Investor
Relations & Corporate Communications 619-302-4431
ir@equilliumbio.com
Equillium (NASDAQ:EQ)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Equillium (NASDAQ:EQ)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024